XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
  AIDS
  Influenza
  MRSA
  Tuberculosis
  Shigella
  HCV
  SARS
  Ebola
  Dengue
  Malaria
  Pertussis
  Mumps
  Prion Diseases
  Small Pox
  Anthrax
  Leishmaniasis
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
 
 India
Search

Last Updated: Nov 18, 2006 - 12:32:53 PM

Anthrax Channel
subscribe to Anthrax newsletter

Latest Research : Infectious Diseases : Anthrax

   DISCUSS   |   EMAIL   |   PRINT
Protective Antigen Ion Channel Asymmetric Blockade To Detect Anthrax Infection
Aug 29, 2005 - 10:04:00 PM, Reviewed by: Dr.

"We hope this system will lead to a method for rapidly screening agents that inhibit the binding of LF or EF to these pores," says NIST's lead investigator John Kasianowicz.

 
A new laboratory method for quickly detecting active anthrax proteins within an infected blood sample at extremely low levels has been developed by researchers at the National Institute of Standards and Technology (NIST), the U.S. Army Medical Research Institute of Infectious Diseases and the National Cancer Institute.

Current detection methods rely on injecting live animals or cell cultures with samples for analysis and require up to several days before results are available. Described* in an upcoming issue of the Journal of Biological Chemistry, the new method produces unambiguous results in about an hour. The researchers hope the system will ultimately be useful in developing fast, reliable ways to diagnose anthrax infections or to quickly screen large numbers of drugs as possible therapies for blocking the bacteria's toxic effects.

The method works by detecting changes in current flow when anthrax proteins are present in a solution. An anthrax protein ironically called "protective antigen" spontaneously forms nanometer-scale pores that penetrate the surface of an organic membrane. When a voltage is applied across the membrane, positively and negatively charged ions flow freely in both directions through the pore. When additional anthrax proteins called lethal factor (LF) or edema factor (EF) are present, however, the proteins bind to the outside of the pore and shut down the flow of ions in one direction. This change in current flow depends on the concentration of the proteins in the solution and can detect amounts as low as 10 picomolar (trillionths of a mole).

"We hope this system will lead to a method for rapidly screening agents that inhibit the binding of LF or EF to these pores," says NIST's lead investigator John Kasianowicz.

Protective Antigen Ion Channel Asymmetric Blockade To Detect Anthrax Infection
A computer model shows side and top views of two different proteins produced by anthrax bacteria. The green molecule is "protective antigen" (PA), which spontaneously forms pores that penetrate organic membranes such as cell walls. The yellow molecule is "lethal factor (LF)." When a voltage is applied across a membrane studded with PA pores, both positive and negative ions flow through. Once LF binds to the pore, however, current only flows in one direction. Image credit: T. Nguyen, National Cancer Institute


Live anthrax antibodies seem to do exactly that. When antibodies were present in the test solution and then LF was added, the current flow remained unchanged, indicating that the anthrax proteins were unable to bind properly. The long-term goal would be to find drugs with few side effects that also interfere with this binding process.
 

- K.M. Halverson, R.G. Panchal, T. Nguyen, R. Gussio, S.F. Little, M. Misakian, S. Bavari and J.J. Kasianowicz, "Anthrax Biosensor: Protective Antigen Ion Channel Asymmetric Blockade," Journal of Biological Chemistry, slated for a November issue, posted online Aug. 8, 2005.
 

National Institute of Standards and Technology (NIST)

 
Subscribe to Anthrax Newsletter
E-mail Address:

 



Related Anthrax News

Monoclonal antibody recognizes a specific sugar on the surface of anthrax bacteria spores
Scientists design functionalized liposome - a potent anthrax toxin inhibitor
PlyPH protein kills anthrax bacteria by exploding their cell walls
Surprising new insights about the acid pH levels required for anthrax toxin
Diagnostic method for identifying Bacillus anthracis receives FDA approval
Protective Antigen Ion Channel Asymmetric Blockade To Detect Anthrax Infection
ABthrax(TM) Safe and Effective against Anthrax
DNI - Newly Identified Inhibitor of Anthrax Toxin May Contribute to Postexposure Therapy


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us